Liver Cnacer: Tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) in preventing recurrence after radical resection of BCLC stage 0/A hepatocellular carcinoma

It is still unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment will affect the recurrence and death of patients after radical resection for hepatitis B virus-related hepatocellular carcinoma (HCC) It's different

It is still unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment will affect the recurrence and death of patients after radical resection for hepatitis B virus-related hepatocellular carcinoma (HCC) It's different

From January 2010 to December 2019, 20,572 HCC patients undergoing liver resection were screened

From January 2010 to December 2019, 20,572 HCC patients undergoing liver resection were screened

With a median follow-up of 52.

RFS

Postoperative less than 2 years is defined as early recurrence, ≥ 2 years is defined as late recurrence

Early and late RFS

The 1-year, 3-year, and 5-year transplant-free overall survival rates in the ETV group were 98.

The 1-year, 3-year, and 5-year transplant-free overall survival rates in the ETV group were 98.

OS

In summary, studies have shown that after radical resection of HBV-related HCC patients, TDF treatment is significantly associated with a lower risk of HCC recurrence, especially late recurrence

In summary, studies have shown that after radical resection of HBV-related HCC patients, TDF treatment is significantly associated with a lower risk of HCC recurrence, especially late recurrence

Original source:

Ming-Chao Tsai, Chih-Chi Wang, Wei-Chen Lee, et al.

Ming-Chao Tsai, Chih-Chi Wang, Wei-Chen Lee, et al.
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection.
Liver Cancer.
DOI: 10.
1159/000518940.
Published online: September 21, 2021.


Leave a message here